^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:tunlametinib (HL-085) (MEK inhibitor, MEK1 inhibitor, MEK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

    Excerpt:
    ...NRAS mutation at baseline;....
    Trial ID:
    NCT06008106
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of HL-085 in NRAS Mutant Advanced Melanoma

    Excerpt:
    ...Subjects must have NRAS mutation in melanoma....
    Trial ID:
    NCT03973151
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    HL-085 in NRAS-mutated Advanced Melanoma

    Excerpt:
    ...- Able to provide the genetic test report with documented NRAS mutation at baseline....
    Trial ID:
    NCT05217303
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.

    Published date:
    05/25/2023
    Excerpt:
    Tunlametinib was well tolerated and demonstrated encouraging treatment response rate in pts with advanced NRAS-mutant melanoma.
    DOI:
    10.1200/JCO.2023.41.16_suppl.9510
    Trial ID:
    NCT05217303